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Abstract
Some tobacco researchers have argued that the European Union should remove its ban on a form
of low-nitrosamine smokeless tobacco referred to as Swedish 'snus'. This argument has developed
in to an international debate over the use of smokeless tobacco as a measure of harm reduction
for smokers. Leading authorities in the USA have firmly stated that there is no safe tobacco - a
message which does not allow for any discussion of comparative tobacco risks. This commentary
is intended to review the origin of the controversy over Swedish 'snus', to examine briefly the
meta-analysis on cancer risks by Peter Lee and Jan Hamling (published in July in BMC Medicine) and
to discuss the anticipated direction of the debate on tobacco-harm reduction in the USA. We
anticipate that much of the debate will shift from the discussion of epidemiologic data to the
discussion of the marketing, health communication and economics of smokeless tobacco. While the
Food and Drug Administration's newly approved authority over tobacco will undoubtedly affect the
smokeless products, it may not be the sole determinant of harm reduction's fate in the USA.
See associated research article by Lee and Hamling: http://www.biomedcentral.com/1741-7015/7/
36
Origin of the controversy
The controversy over smokeless tobacco, considered by
some as a potential substitute for cigarettes, originates
from epidemiologic studies in Sweden - a country which
has one of the lowest rates of daily smoking in Europe in
recent years [1]. This achievement in tobacco control was
particularly remarkable because of the significant gender
difference in the smoking rates, leading one expert to
question whether an experiment in harm reduction was
underway [2]. The decline in daily smoking over the past
two decades was more pronounced in Swedish males than
in females [3,4], resulting in a lower prevalence by 2001
(15% versus 19%, respectively) [5]. This steep decline
coincided with Swedish males' increased use of 'snus', a
form of moist smokeless tobacco which harbours fewer
cancer-causing nitrosamines than its American counter-
parts [6]. Furthermore, the apparent substitution of
tobacco products by the Swedish males coincided with a
decrease in the incidence of lung cancer, a trend which has
not been observed in Swedish females [7]. It is unlikely
that existing tobacco-control policies could account for
the difference in the prevalence of both smoking and
smoking-related morbidity. Yet it is important to note that
virtually all of the Swedish data supporting the cause of
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harm reduction is based on observational study designs,
notably the cross-sectional design [3,5,8,9]. Thus, it is pre-
mature to state that the increased use of 'snus' is causally
associated with tobacco substitution and the decline in
morbidity. Emerging clinical trials are investigating
smokeless tobacco as a tool for smoking cessation [10]. In
one randomized clinical trial of smokeless-tobacco use in
combination with group support (versus group support
alone), smoking rates decreased at the end of the 7-week
period for the intervention group [11]. This effect, how-
ever, was not maintained after 6 months.
The current debate over harm reduction has focused pri-
marily on two epidemiologic issues. The first relates to the
cancer risk from the use of smokeless products, the basis
for our commentary on the article by Peter Lee and Jan
Hamling [12]. The second issue addresses whether use of
smokeless tobacco is associated with the initiation or ces-
sation of smoking. These issues have increasingly been
investigated in the USA where smokeless tobacco is fre-
quently marketed. Data, based on a single cross-sectional
study [13], suggests that smokers in the USA are exchang-
ing their cigarettes for smokeless tobacco. However, a lon-
gitudinal study of USA residents [14] reported that only
0.3% of male smokers changed to smokeless tobacco
compared to 3.9% of male smokeless-tobacco users who
subsequently changed to smoking tobacco.
The issue concerning the transition from smokeless
tobacco to smoking raises the specter of the gateway effect.
This issue has attracted much attention because of the
belief that non-smoking adolescents could be unduly
influenced to use a form of smokeless tobacco ('snus')
intended for use by established smokers. A gateway effect,
which could consequently lead to an adolescent's uptake
of smoking, has been reported in some USA reports [15-
17] but refuted in others [18,19]. One opposing argument
states that the underlying risk factors for smoking, which
tend to be greater in users of smokeless tobacco, account
for the observed association between the tobacco prod-
ucts. This hypothesis was the basis for our use of the pro-
pensity score [20] in matching the users and non-users of
smokeless tobacco [19]. Smokeless tobacco was a signifi-
cant risk factor for smoking in this longitudinal study, but
only prior to the matching of individuals on the propen-
sity score. Even if a gateway effect to smoking exists, which
is doubtful, only a minority of smokeless-tobacco users
would be affected. Analyses of two national surveys indi-
cate that less than 40% of smokeless-tobacco users in the
USA had initiated use prior to the onset of smoking
[21,22]. The remainder had either never initiated smoking
or had smoked prior to their initial use of smokeless
tobacco.
Commentary on an article by Peter Lee and Jan 
Hamling
A systematic review by Lee and Hamling provides a com-
prehensive assessment of the state of evidence on the rela-
tionship between smokeless tobacco and cancer in Europe
and North America [12]. Carcinogens in smokeless
tobacco include high levels of nitrosamines, polycyclic
aromatic hydrocarbons and other agents [23], underscor-
ing the biologic relevance of this type of analysis. The pri-
mary findings of Lee and Hamling are that oropharyngeal
cancers, in addition to prostate cancer (an association that
may be spurious as it lacks biologic plausibility and is
unsupported by prior research), were the only malignan-
cies significantly associated with smokeless-tobacco use
[12].
Researchers in cancer prevention refer to oropharyngeal
cancer (along with cancers of the lung, esophagus and
stomach) as an aerodigestive malignancy, a heterogene-
ous group of epithelial tumours affected by 'field carcino-
genesis' from a common exposure - inhaled tobacco
smoke. Beyond alcohol and tobacco smoking, recent evi-
dence has implicated a new aetiologic factor for a subset
of oropharyngeal and laryngeal cancer patients: human
papilloma virus (HPV) [24]. In contrast to other oropha-
ryngeal cancers, HPV-associated oropharyngeal cancers
occur in younger patients and are characterized by an
equal gender distribution, a lower tumour grade of differ-
entiation, less association with alcohol and tobacco use
and improved survival outcomes. The relevant oropha-
ryngeal cancer-associated HPV serotypes (HPV 16, 18,
others) and mode of transmission (sexual) are common
to cervical cancer. Clearly, HPV-status was not reported in
the individual studies reviewed in this meta-analysis, but
smokeless-tobacco use has been associated with young
age [25] and risky behaviour (including youth rebellious-
ness and pressure to be sexually active) [26]. Although
HPV status is a potential confounder for the reported asso-
ciation of smokeless tobacco with oropharyngeal cancer,
it is unlikely to explain the excess risk observed in the Lee
and Hamling article - an effect that is consistent with other
reports [25].
This lack of association of smokeless-tobacco use with
cancers of the lung, esophagus, stomach, pancreas, blad-
der, kidney and haematologic malignancies starkly con-
trasts with research published over the past six decades on
smoking-related cancer risks [27-29]. Despite the observa-
tional nature of these results, the overwhelmingly null
associations with cancer in this high quality analysis are
provocative, if not compelling. It is important to note that
these results are not entirely congruent with prior reports
on smokeless-tobacco use which demonstrate an
increased risk of oral, esophageal and pancreas cancersBMC Medicine 2009, 7:61 http://www.biomedcentral.com/1741-7015/7/61
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[25]. Potential reasons for the apparent discrepancies are
discussed by Lee and Hamling in a separate paper [30].
Future directions
Attention in the coming years is likely to shift from an epi-
demiologic debate to a debate on the marketing, health
communication and economics of the smokeless prod-
ucts. In Europe, researchers and policymakers will con-
tinue to debate the European Union's ban on 'snus' [31].
In the USA, attention will most likely be focused on the
tobacco industry's marketing of the 'snus'-like products.
This, of course, will depend greatly on the Food and Drug
Administration's (FDA) newly approved regulation of the
tobacco industry [32]. A historical examination of tobacco
documents reveals that the Philip Morris company had
anticipated smoking restrictions and the benefits of
smokeless products as early as 1984 [33]. As a conse-
quence, cigarette manufacturers have invested resources
into the smokeless-tobacco market.
A question of primary interest is whether the tobacco
companies will market 'snus' (for example, Camel Snus)
for harm reduction, given FDA approval, or market the
tobacco as a situational substitute for the smokers who
frequently encounter smoking restrictions. Carpenter et
al.'s examination suggests that the industry is more inter-
ested in the dual use of tobacco products, rather than
tobacco substitution [33]. A scenario of graver concern is
that adolescents will use 'snus' because the tobacco is mis-
perceived as being safe. The low level of nicotine delivery
in Marlboro Snus [34], a level insufficient for supplanting
cigarettes, elicits memories of the graduation strategy [35]
and the related manipulation of the 'free' nicotine content
of moist snuff [36]. It is yet to be determined when and if
the FDA will regulate the nicotine yields of the smokeless
products. The FDA will, however, mandate that tobacco
companies provide sufficient evidence of harm reduction
before such a claim can be stated publically [37]. This
position reflects the sentiment of other state and federal
agencies (for example the US Center for Disease Control
and Prevention) which are reluctant to disseminate infor-
mation on comparative tobacco risks. This reluctance may
be in response to the wide variation in toxicant levels of
smokeless products [38]. Others have argued, however,
that such a position is a violation of smokers' rights to be
given accurate information [39], and may be a factor
which could account for the preponderance of misper-
ceived tobacco risks [40-43]. Risk perceptions aside, most
smokers are not receptive to using smokeless tobacco as a
substitute, a finding reported in the 2005 California
Tobacco Survey [44]. Thus, factors other than the FDA's
oversight, such as a cultural influence on 'snus' use [45],
may ultimately determine the fate of tobacco-harm reduc-
tion in the USA.
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